Milestone Pharmaceuticals Inc. Files 10-K/A Amendment for Fiscal Year Ended Dec 31, 2023

TL;DR

<b>Milestone Pharmaceuticals Inc. has filed an amended 10-K report for the fiscal year ending December 31, 2023, with its common shares listed on the Nasdaq under MIST.</b>

AI Summary

Milestone Pharmaceuticals Inc. (MIST) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Milestone Pharmaceuticals Inc. filed an amended 10-K report for the fiscal year ending December 31, 2023. The company's common shares trade on The Nasdaq Stock Market LLC under the ticker symbol MIST. Milestone Pharmaceuticals Inc. is incorporated in Quebec, Canada. The principal executive offices are located at 1111 Dr. Frederik-Phillips Boulevard, Suite 420, Montreal, Quebec, H4M 2X6. The company's telephone number is (514) 336-0444.

Why It Matters

For investors and stakeholders tracking Milestone Pharmaceuticals Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's current financial health and strategic direction. The filing confirms the company's listing on the Nasdaq, indicating its status as a publicly traded entity and providing a reference point for market performance analysis.

Risk Assessment

Risk Level: low — Milestone Pharmaceuticals Inc. shows low risk based on this filing. The filing is an amendment to a previous 10-K, suggesting potential corrections or additions to previously reported information, but the nature of the amendment is not detailed in this header information.

Analyst Insight

Monitor future filings for details on the amendments made to the 10-K report to understand any changes in the company's financial or operational status.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported fiscal year end)
• 2024-04-29 — Filing Date (Date the 10-K/A was filed)
• MIST — Trading Symbol (Symbol for Milestone Pharmaceuticals Inc. common shares)
• 001-38899 — Commission File Number (SEC commission file number for the registrant)

Key Players & Entities

• Milestone Pharmaceuticals Inc. (company) — Registrant name
• MIST (company) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange where common shares are registered
• 2023-12-31 (date) — Fiscal year end
• 2024-04-29 (date) — Filing date
• Montreal (location) — City of principal executive offices
• Quebec (location) — State/Province of incorporation and principal executive offices
• 001-38899 (other) — Commission file number

FAQ

Industry Context

Milestone Pharmaceuticals Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of drugs.

Regulatory Implications

The company is subject to SEC regulations for public reporting, including the requirement to file annual reports (10-K) and amendments (10-K/A).

What Investors Should Do

1. Review the full amended 10-K filing for specific details on changes or additions made.
2. Analyze the company's financial performance and operational updates for the fiscal year 2023.
3. Track the stock performance of MIST on the Nasdaq for investment decisions.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K/A filing.
• 2024-04-29: Filing Date — Date the amended 10-K report was submitted to the SEC.

Year-Over-Year Comparison

This is an amended 10-K filing (10-K/A), indicating updates or corrections to the original 10-K filed for the fiscal year ended December 31, 2023.

Filing Documents

• tm2412907d1_10ka.htm (10-K/A) — 326KB
• tm2412907d1_ex31-3.htm (EX-31.3) — 4KB
• tm2412907d1_ex31-4.htm (EX-31.4) — 4KB
• 0001104659-24-054157.txt (&nbsp;) — 598KB
• mist-20231231.xsd (EX-101.SCH) — 3KB
• mist-20231231_lab.xml (EX-101.LAB) — 36KB
• mist-20231231_pre.xml (EX-101.PRE) — 24KB
• tm2412907d1_10ka_htm.xml (XML) — 6KB

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 4

Executive Compensation

Item 11. Executive Compensation 11

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 19

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 23

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 26 PART IV 27

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 27

SIGNATURES

SIGNATURES 30 "Milestone Pharmaceuticals" and the Milestone logo appearing in this Amendment No. 1 to the Annual Report on Form 10-K are unregistered trademarks of Milestone Pharmaceuticals Inc. All other trademarks, trade names and service marks appearing in this Amendment No. 1 to the Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Amendment No. 1 to the Annual Report on Form 10-K may be referred to without the and symbols, but such references should not be construed as any indicator that their respective This Amendment No. 1 to the Annual Report on Form 10-K contains references to United States dollars and Canadian dollars. All dollar amounts referenced, unless otherwise indicated, are expressed in United States dollars. References to "$" are to United States dollars and references to "C$" are to Canadian dollars. 2 EXPLANATORY NOTE The purpose of this Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K (the "Amendment") is to amend and restate Part III, Items 10 through 14 of the previously filed Annual Report on Form 10-K of Milestone Pharmaceuticals Inc. (the "Company") for the year ended December 31, 2023 (the "Form 10-K"), filed with the Securities and Exchange Commission on March 21, 2024, to include information previously omitted in reliance on General Instruction G(3) to Form 10-K, which provides that registrants may incorporate by reference certain information from a definitive proxy statement prepared in connection with the election of directors within 120 days after the fiscal year end. The Company has determined to include such Part III information by amendment of the Annual Report on Form 10-K rather than incorporation by reference to the proxy statement. Accordingly, Part III is hereby amended and restated as set forth below. In addition, this Amendment deletes the reference on the cover of the For

DIRECTORS, EXECUTIVE OFFICERS AND

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Information About our Directors The following table sets forth the names and ages, as of April 29, 2024, of each member of our board of directors (the "Board"), and the subsequent narrative provides details about each of the Director nominees' background and experience. NAME AGE POSITION(S) DIRECTOR SINCE RESIDENCE Robert J. Wills 70 Director and Chair of the Board October 2020 New Jersey (USA) Seth H.Z. Fischer 68 Director March 2023 New Jersey (USA) Lisa M. Giles 65 Director October 2020 South Carolina (USA) Debra K. Liebert 68 Director June 2015 California (USA) Joseph Oliveto 57 President, Chief Executive Officer and Director July 2017 North Carolina (USA) Richard Pasternak 75 Director November 2019 New York (USA) Michael Tomsicek 58 Director April 2019 Wisconsin (USA) Robert J. Wills has served as a member of our board since October 2020. He has over 35 years of extensive and significant experience in the pharmaceutical industry, including preclinical and clinical research and development, business development and strategic partnering. Dr. Wills served in a variety of executive roles for Johnson & Johnson ("J&J") a medical device, pharmaceutical and consumer goods manufacturing company, from December 1989 to February 2015 and recently served as Vice President, Alliance Manager where he was responsible for managing strategic alliances for J&J's Pharmaceutical Group worldwide since 2002. Prior to this, Dr. Wills spent 22 years in pharmaceutical drug development, 12 of which were at J&J and 10 of which were at Hoffmann-La Roche Inc. Before assuming his role as Vice President, Alliance Manager at J&J, Dr. Wills served as Senior Vice President Global Development at J&J where he was responsible for its late stage development pipeline and was a member of several internal commercial and research and development operating

View Full Filing

View this 10-K/A filing on SEC EDGAR